| Literature DB >> 35190422 |
Patrícia Mayara Moura da Silva1,2, Ana Beatriz Oliveira Bezerra3, Luanna Barbara Araújo Farias3, Tatiana Souza Ribeiro3, Edgard Morya2, Fabrícia Azevêdo da Costa Cavalcanti3.
Abstract
INTRODUCTION: Type 2 diabetes can lead to gait abnormalities, including a longer stance phase, shorter steps and improper foot pressure distribution. Quantitative data from objective methods for evaluating gait patterns are accurate and cost-effective. In addition, it can also help predictive methods to forecast complications and develop early strategies to guide treatments. To date, no research has systematically summarised the predictive methods used to assess type 2 diabetic gait. Therefore, this protocol aims to identify which predictive methods have been employed to assess the diabetic gait. METHODS AND ANALYSIS: This protocol will follow the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocol (PRISMA-P) statement. Electronic searches of articles from inception to January 2022 will be performed, from May 2021 to 31 January 2022, in the Web of Science, MEDLINE, Embase, IEEE Xplore Digital Library, Scopus, CINAHL, Google Scholar, APA PsycInfo, the Cochrane Library and in references of key articles and grey literature without language restrictions. We will include studies that examined the development and/or validation of predictive methods to assess type 2 diabetic gait in adults aged >18 years without amputations, use of assistive devices, ulcers or neuropathic pain. Two independent reviewers will screen the included studies and extract the data using a customised charting form. A third reviewer will resolve any disagreements. A narrative synthesis will be performed for the included studies. Risk of bias and quality of evidence will be assessed using the Prediction Model Risk of Bias Assessment Tool and the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis. ETHICS AND DISSEMINATION: Ethical approval is not required because only available secondary published data will be analysed. The findings will be disseminated through peer-reviewed journals and/or presentations at relevant conferences and other media platforms. PROSPERO REGISTRATION NUMBER: CDR42020199495. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: biotechnology and bioinformatics; diabetes and endocrinology; neurophysiology
Mesh:
Year: 2022 PMID: 35190422 PMCID: PMC8862448 DOI: 10.1136/bmjopen-2021-051981
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Preferred Reporting Items for Systematic Reviews and Meta-Analysis flow diagram for the identification, screening and eligibility of included articles.
Example of the data extraction form for all included studies
|
| |
| Study year | Year of the study publication |
| Author information | Last name of the author, whether clinical practitioners participated in the study |
| Type of study | Source of data (eg, cohort, case-control, randomised trial participants or registry data) |
| Journal name | Journal name |
| PICO elements | PICO elements in summary |
|
| |
| Database name | Name of the database used for modelling |
| Host organisation | Name of the hosting organisation of the database |
| Sponsorship | The funding or sponsorship information |
| Sample size | Sample size used for building the model |
| Source or data | From which source the database was used (eg, electronic health records, clinical registry, administrative data, cohort study, clinical trial) |
|
| |
| Gender | Sex of adults (male, female, alternative gender) |
| Age | Age and/or year of birth |
| Country | Country or countries in which study was based |
| Diabetes severity | Disease severity |
|
| |
| Predictors | Timing of predictor measurement (eg, at patient presentation, at diagnosis, at treatment initiation) |
| Number of features | Number of features for building the model |
| Selected features | Did the study reported the importance of selected features? |
| Type of extracted feature | Which features the algorithm uses (eg, pressure, gait velocity, cadence, step width, pixel feature, action unit) |
| Tool used for gait assessment | Quantitative tool used to assess gait kinetic or kinematic (eg, IMU, force platform, optoelectronic, EMG) |
| Used highly rated standard devices | Quantitative tool used to assess gait kinetic or kinematic was a device considered as gold standard (eg, force platform, optoelectronic) |
| Predictive method used | Type of predictive method used to assess gait (eg, which machine learning techniques were used) |
| Model name | The name of the predictive model used. The underlying mathematical model used (eg, linear regression, support vector machine) |
| Missing data | Number of participants with missing data for each predictor and the process handled with missing data (eg, complete-case analysis, imputation or other methods) |
| Format of input feature (predictor or variables) | Which input gait data were used (eg, plantar pressure, frame, sequence or image) |
| Model performance/ validation | Performance metrics and scores of how accurate the model used is predicting (eg, accuracy, average errors, R-squared, confusion matrix) |
| Model evaluation | Method used for testing model performance: development dataset only (random split of data, resampling methods, eg, bootstrap or cross-validation) or separate external validation (eg, temporal, geographical, different setting, different investigators) |
| Computational efficiency and cost | Computational efficiency (speed, cloud space, etc) and cost related to the algorithm (eg, require GPU resources, large cluster) |
EMG, electromyography; GPU, graphics processing unit; IMU, inertial measurement unit; PICO, population, intervention (exposure), control, outcome.